AIM: To identify the differentially secreted proteins or polypeptides associated with tumorigenesis of esophageal squamous cell carcinoma (ESCC) from serum and to find potential tumor secreted biomarkers. METHODS: Proteins from human ESCC tissue and its matched adjacent normal tissue; pre-surgery and post-surgery serum; and pre-surgery and normal control serum were separated by two-dimensional electrophoresis (2-DE) to identify differentially expressed proteins. The silver-stained 2-DE were scanned with digital ImageScanner and analyzed with ImageMaster 2D Elite 3.10 software. A cluster of protein spots differentially expressed were selected and identified with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). One of the differentially expressed proteins, clusterin, was down-regulated in cancer tissue and pre-surgery serum, but it was reversed in post-surgery serum. The results were confirmed by semi-quantitative reverse-transcription (RT)-PCR and western blot. RESULTS: Comparisons of the protein spots identified on the 2-DE maps from human matched sera showed that some proteins were differentially expressed, with most of them showing no differences in composition, shape or density. Being analyzed by MALDI-TOF-MS and database searching, clusterin was differentially expressed and down-regulated in both cancer tissue and pre-surgery serum compared with their counterparts. The results were also validated by RT-PCR and western blot. CONCLUSION: The differentially expressed clusterin may play a key role during tumorigenesis of ESCC. The 2DE-MS based proteomic approach is one of the powerful tools for discovery of secreted markers from peripheral.
AIM: To identify the differentially secreted proteins or polypeptides associated with tumorigenesis of esophageal squamous cell carcinoma (ESCC) from serum and to find potential tumor secreted biomarkers. METHODS: Proteins from human ESCC tissue and its matched adjacent normal tissue; pre-surgery and post-surgery serum; and pre-surgery and normal control serum were separated by two-dimensional electrophoresis (2-DE) to identify differentially expressed proteins. The silver-stained 2-DE were scanned with digital ImageScanner and analyzed with ImageMaster 2D Elite 3.10 software. A cluster of protein spots differentially expressed were selected and identified with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). One of the differentially expressed proteins, clusterin, was down-regulated in cancer tissue and pre-surgery serum, but it was reversed in post-surgery serum. The results were confirmed by semi-quantitative reverse-transcription (RT)-PCR and western blot. RESULTS: Comparisons of the protein spots identified on the 2-DE maps from human matched sera showed that some proteins were differentially expressed, with most of them showing no differences in composition, shape or density. Being analyzed by MALDI-TOF-MS and database searching, clusterin was differentially expressed and down-regulated in both cancer tissue and pre-surgery serum compared with their counterparts. The results were also validated by RT-PCR and western blot. CONCLUSION: The differentially expressed clusterin may play a key role during tumorigenesis of ESCC. The 2DE-MS based proteomic approach is one of the powerful tools for discovery of secreted markers from peripheral.
Authors: C R Yang; K Leskov; K Hosley-Eberlein; T Criswell; J J Pink; T J Kinsella; D A Boothman Journal: Proc Natl Acad Sci U S A Date: 2000-05-23 Impact factor: 11.205
Authors: A S Vercoutter-Edouart; J Lemoine; X Le Bourhis; H Louis; B Boilly; V Nurcombe; F Révillion; J P Peyrat; H Hondermarck Journal: Cancer Res Date: 2001-01-01 Impact factor: 12.701
Authors: I Viard; P Wehrli; L Jornot; R Bullani; J L Vechietti; J A Schifferli; J Tschopp; L E French Journal: J Invest Dermatol Date: 1999-03 Impact factor: 8.551
Authors: M Oka; K Yamamoto; M Takahashi; M Hakozaki; T Abe; N Iizuka; S Hazama; K Hirazawa; H Hayashi; A Tangoku; K Hirose; T Ishihara; T Suzuki Journal: Cancer Res Date: 1996-06-15 Impact factor: 12.701
Authors: Ge Zhou; Hongmei Li; Dianne DeCamp; She Chen; Hongjun Shu; Yi Gong; Michael Flaig; John W Gillespie; Nan Hu; Philip R Taylor; Michael R Emmert-Buck; Lance A Liotta; Emanuel F Petricoin; Yingming Zhao Journal: Mol Cell Proteomics Date: 2002-02 Impact factor: 5.911
Authors: Linda Vona-Davis; Timothy Vincent; Sara Zulfiqar; Barbara Jackson; Dale Riggs; David W McFadden Journal: J Gastrointest Surg Date: 2004-12 Impact factor: 3.452
Authors: Shen Hu; Martha Arellano; Pinmanee Boontheung; Jianghua Wang; Hui Zhou; Jiang Jiang; David Elashoff; Roger Wei; Joseph A Loo; David T Wong Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531